Search
Omaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Haloperidol
go.drugbank.com/drugs/DB00502ApprovedInvestigational[A180625] The efficacy of haloperidol was first established in controlled trials in the 1960s.[A180610] … However, these findings contradict the findings from studies in vitro with human liver microsomes and from drug interaction studies in vivo.
Products: MYUNG IN HALOPERIDOL TABLET 1.5 mg, MYUNG IN HALOPERIDOL INJECTION 5 mg/mlCrisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalThis non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. … It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile.
Propiomazine
go.drugbank.com/drugs/DB00777ApprovedPropiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. … Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism.
Vorapaxar
go.drugbank.com/drugs/DB09030ApprovedBy inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation. … Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history
Synonyms: Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamateIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalThe PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer … co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
Vayarin
go.drugbank.com/drugs/DB09328ApprovedVayarin is an orally administered prescription medical food for the clinical dietary management of complex lipid imbalances thought to be associated with ADHD. … Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503].
Fosamprenavir
go.drugbank.com/drugs/DB01319ApprovedInvestigationalFosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
Zavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigational[A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults. … CGRP receptors are expressed in the central and peripheral nervous system; however, CGRP does not cross the blood-brain barrier, suggesting that it acts on peripheral nerves.
Synonyms: 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-Eftrenonacog alfa
go.drugbank.com/drugs/DB11608ApprovedIt was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. … Hemophilia B is a blood disorder with an incidence of approximately once every 30,000 male births in all populations and ethnic groups [A31557].